BIOS Capital Management, LP
In its 13F for Q3 2025 (holdings as of September 30, 2025, filed November 12, 2025), BIOS Capital Management, LP reported 6 stock positions worth $88.9 million. Its top holding was Actuate Therapeutics (ACTU) at 75.6% of the portfolio, followed by Cognition Therapeutics (CGTX, 9.1%) and Opus Genetics (IRD, 7.4%). Compared with Q2 2025, it added to 1 and reduced 1. The biggest buy was Actuate Therapeutics (ACTU, shares +1%) and the biggest sale Lantern Pharma (LTRN, shares −6%).
- Most Recent 13F
- Q2 2026
- Location
- Fort Worth, TX
- CIK
- 0001813845
- Portfolio Value
- $88.9M (Q3 2025)
- SEC Filing
- 0001104659-25-110482 ↗ filed Nov 12, 2025
Holdings Value
Holdings 6 stocks · $88.9M
| ACTU Actuate Therapeutics Inc. | 75.62% | 10,049,996 | $67.2M | Add +0.8% |
| CGTX Cognition Therapeutics Inc. | 9.11% | 6,000,000 | $8.1M | No change |
| IRD Opus Genetics Inc. | 7.42% | 3,683,429 | $6.6M | No change |
| LTRN Lantern Pharma Inc. | 4.97% | 1,015,715 | $4.4M | Reduce -5.6% |
| RNTX Rein Therapeutics Inc. | 2.19% | 1,690,751 | $1.9M | No change |
| INAB IN8BIO Inc. | 0.70% | 286,664 | $622K | No change |
Portfolio Sells Q2 2025 → Q3 2025
| LTRN Lantern Pharma Inc. | Reduce -5.6% | 4.97% | +0.28 |
Portfolio Buys Q2 2025 → Q3 2025
| ACTU Actuate Therapeutics Inc. | Add +0.8% | 75.62% | −8.28 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 6 | $41.7M | ACTU, IRD, CGTX, RNTX, LTRN |
| Q1 2026 | 6 | $52.9M | ACTU, IRD, CGTX, RNTX, LTRN |
| Q4 2025 | 6 | $82.6M | ACTU, CGTX, IRD, LTRN, RNTX |
| Q3 2025 | 6 | $88.9M | ACTU, CGTX, IRD, LTRN, RNTX |
| Q2 2025 | 6 | $72.6M | ACTU, IRD, LTRN, RNTX, CGTX |
| Q1 2025 | 6 | $79.2M | ACTU, LTRN, RNTX, CGTX, INAB |
| Q4 2024Amended | 6 | $94.1M | ACTU, CGTX, RNTX, LTRN, INAB |